EGFR and cancer: Together, our data indicate that EGFR-targeted hDT806 inhibits cancer cell proliferation and suppresses the growth of xenograft tumors by interfering with multiple cellular processes, such as the disruption of EGFR signaling, inhibition of transcription, DNA damage, as well as apoptotic response.